A low-cost amino acid sold in energy drinks and supplement aisles has become one of the more intriguing candidates in longevity research. A 2023 study in Science, led by Vijay Yadav's group at Columbia University and the National Institute of Immunology in New Delhi, reported that circulating taurine falls steadily with age in mice, monkeys and humans. Restoring it in animals improved health and, in rodents, extended life. The headline number is a lifespan gain of roughly 10-12% in mice. That figure is striking, but it needs context before anyone reaches for a tub of powder.
What the researchers found
Taurine is a sulfur-containing amino acid found in meat, fish and dairy. The body also makes it in small amounts. It supports bile acid conjugation, osmoregulation, mitochondrial function and antioxidant defense. The research team measured blood levels across species and found a consistent downward trend with age. In humans the drop was large, with levels in older adults far below those in children.
The team then tested whether the decline mattered. Middle-aged mice, about 14 months old, received daily taurine supplementation. Their median lifespan increased by about 10% in males and 12% in females, according to the paper's reporting. Treated animals also showed better markers of healthspan, including:
- Improved bone density and muscle endurance
- Better glucose handling and less weight gain
- Reduced anxiety-like and depressive-like behavior
- Healthier immune and metabolic profiles
In worms, taurine also extended lifespan. In a smaller, shorter study of middle-aged rhesus monkeys, supplementation improved healthspan markers such as body weight, bone mineral density, blood sugar and liver injury indicators. Monkey lifespan was not measured, because that experiment would take decades.
Why it might work
The authors describe taurine as acting on several hallmarks of aging at once. In cells and animals, supplementation reduced markers of cellular senescence, the buildup of dysfunctional "zombie" cells. It lessened DNA damage, protected against mitochondrial dysfunction, helped in telomerase-deficient models, and dampened the chronic low-grade inflammation known as inflammaging. This broad profile suggests taurine may be a supporting player in cellular maintenance rather than a single-target drug.
The human evidence
The human data in the paper are observational. In a large European cohort, lower taurine levels tracked with conditions such as obesity, type 2 diabetes, hypertension and heightened inflammation. Taurine also rose after acute endurance exercise in several groups of people, which hints that part of exercise's benefit could involve this molecule.
These are correlations. Low taurine could drive disease, or disease and poor metabolic health could lower taurine. The authors acknowledge this and conclude only that clinical trials "seem warranted."
What about human doses?
The mouse doses were high, in the range of hundreds of milligrams to about a gram per kilogram of body weight daily. Scaling to humans by body surface area is imprecise, but commentators have estimated equivalent human doses on the order of a few grams per day, with a wide range of uncertainty depending on the method. For comparison:
- A typical energy drink contains around 1 gram of taurine.
- European food safety assessments have considered intakes up to about 3 grams per day as observed safe in healthy adults.
- Clinical studies in conditions such as heart failure and diabetes have used roughly 1.5 to 6 grams daily, generally with good tolerability over limited periods.
No trial has established an optimal or proven anti-aging dose in people. Anyone with kidney disease, those on medication for blood pressure or heart conditions, and pregnant individuals should speak with a clinician first. Extrapolating from mice is also a known source of failed longevity promises.
Evidence level and caveats
Several points temper the excitement:
- Mice are not people. Many interventions that extend mouse lifespan, often by similar margins, have not translated to humans.
- No human lifespan data. The monkey work covered healthspan markers over months, not survival.
- Association is not causation. The link between low taurine and disease in people does not show that supplementation would reverse it.
- Declines may not be universal. Follow-up work and commentary have questioned how consistently taurine falls with age and how well blood levels reflect tissue stores. The "taurine deficiency drives aging" claim remains a hypothesis under active debate.
- Conflicts of interest. Columbia University has filed provisional patent applications on which senior author Vijay Yadav is an inventor, a standard disclosure but worth noting.
- Diet matters. People who eat meat and seafood already get substantial taurine, so benefits might be largest in those with low intake or increased needs, a question the study cannot answer.
Why it still matters
Taurine is inexpensive, widely available and has a long record of use at moderate doses, which makes it unusually practical to test. It also fits a broader picture in which aging involves the gradual loss of protective circulating molecules, some of which might be replaced. The authors' call for randomized trials is reasonable: measure baseline taurine, supplement at defined doses, and track functional outcomes such as glucose control, muscle strength, inflammation and bone health.
Until those results arrive, taurine is best viewed as a promising lead rather than an established longevity tool. A 10-12% extension in mouse lifespan is a meaningful signal, but the path from that signal to a recommendation for people runs through trials that have not yet been completed.
